Title Information
Title
Testing altered learning in the D2 corticostriatal pathway with antipsychotic exposure
Name: Personal
Name Part
Hill, Melissa
Role
Role Term: Text
creator
Name: Personal
Name Part
Warwick, Hunter
Role
Role Term: Text
creator
Name: Personal
Name Part
Vierling-Claassen, Nathan
Role
Role Term: Text
advisor
affiliation
Brown University. Department of Neuroscience
Name: Personal
Name Part
Frank, Michael
Role
Role Term: Text
advisor
affiliation
Brown University. Department of Cognitive, Linguistic and Psychological Sciences
Name: Personal
Name Part
Moore, Christopher
Role
Role Term: Text
advisor
affiliation
Brown University. Department of Neuroscience
Name: Personal
Name Part
Bath, Kevin
Role
Role Term: Text
advisor
Name: Corporate
Name Part
Brown University. Undergraduate Teaching and Research Award
Role
Role Term: Text
research program
Type of Resource
still image
Genre (aat)
posters
Origin Information
Place
Place Term: Text
Providence
Publisher
Brown University
Date Created (keyDate="yes", encoding="w3cdtf")
2015-08-07
Physical Description
Extent
1 poster
digitalOrigin
reformatted digital
Language
Language Term
eng
Abstract
Antipsychotic medications can be successful in alleviating the positive symptoms of psychosis, such as delusions and hallucinations, but are unsuccessful at treating the negative symptoms of schizophrenia, including emotional flatness and lack of motivation. Antipsychotic medications, such as Haloperidol, are Dopamine D2 receptor blockers and are involved in learning, motivation, reward, movement and coordination. There is evidence that a blockade of D2 receptors can bias individuals to learn more from \"negative\" outcomes, and that this can be due to an altered balance of receptor activation in regions of the cortico-striatal pathway responsible for reward processing. In other words, certain pathways in the brain become strengthened such that there is a bias toward learning from negative outcomes and omission of expected rewards. Our prediction is that a long-term D2 blockade, such as during antipsychotic treatment with Haloperidol, may generate increased learning from negative outcomes and suppressed motivation, possibly contributing to lack of efficacy in the treatment of negative symptoms of schizophrenia.
Subject (LCSH)
Topic
Neurosciences
Subject (LCSH)
Topic
Antipsychotic drugs
Subject (LCSH)
Topic
Schizophrenia
Subject (LCSH)
Topic
Dopamine
Subject (Local)
Topic
Haloperidol
Identifier: DOI
10.26300/x18h-nh36